Turnstone Biologics, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Ottawa Canada (2015)

Organization Overview

First Clinical Trial
2016
NCT02879760
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Turnstone Biologics | Turnstone Biologics, Corp. | Turnstone Biologics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 1)

Lung Neoplasms (Phase 2)

Melanoma (Phase 1)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 11